Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 1

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

NCT05095727 · View on ClinicalTrials.gov ↗

Study Summary

The main goal of this trial is to evaluate the safety and tolerability of mRNA-3745 via intravenous (IV) administration in adult and pediatric participants with GSD1a.

Conditions Studied

Interventions

  • DRUG mRNA-3745

Study Locations (16)

Other

  • AP-HP - Hôpital Antoine Béclère — Clamart
  • CHRU Tours - Hopital Clocheville — Tours
  • Universitair Medisch Centrum Groningen — Groningen
  • Instytut Pomnik Centrum Zdrowia Dziecka — Warsaw
  • Hospital Universitario 12 de Octubre — Madrid
  • Hospital Regional Universitario de Malaga — Málaga

Texas

  • The University of Texas Health Science Center at Houston — Houston
  • Baylor College of Medicine — Houston

Connecticut

  • University of Connecticut Health Center — Farmington

Massachusetts

  • Boston Children's Hospital — Boston

North Carolina

  • Duke University Medical Center — Durham

Ohio

  • Cincinnati Children's Hospital Medical Center — Cincinnati

Pennsylvania

  • Children's Hospital of Philadelphia — Philadelphia

Utah

  • University of Utah — Salt Lake City

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2022-06-01
Est. Completion 2026-11-30
Phase Phase 1

Sponsor

ModernaTX

67 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05095727

The ClinicalTrials.gov registry entry for NCT05095727 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 67 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Glycogen Storage Disease appearing as the primary indexed condition, and to 1 intervention — of which mRNA-3745 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05095727 reports 16 study locations spanning 10 distinct geographic areas — top geographies include Other, Texas, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05095727 about?

NCT05095727 is a clinical study titled "A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)". The main goal of this trial is to evaluate the safety and tolerability of mRNA-3745 via intravenous (IV) administration in adult and pediatric participants with GSD1a.

What is the current status of trial NCT05095727?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-06-01. Estimated completion is 2026-11-30.

What conditions does trial NCT05095727 study?

This clinical trial studies the following conditions: Glycogen Storage Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05095727?

The interventions under investigation include: mRNA-3745 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05095727?

This trial is sponsored by ModernaTX, which has 67 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05095727 being conducted?

This trial has 16 study locations across Connecticut, Massachusetts, North Carolina, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial